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Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine
Tumors (panNETs) are scanty.
Aim: To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting.
Patients and methods: Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was
assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable
disease (SD) þ partial response þ complete response). Data are reported as median (25the75th IQR).
Results: Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET
G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before
sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10
months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11
months and 8 months, respectively), and between patients who had received 3 vs 2 therapeutic
approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and
SD was the most frequent observed response, occurring in 43 pts (53.8%). Overall, 59 pts (73.8%) expe-
rienced AEs, which were grade 1e2 in 43 of them (72.9%), grade 3 in 15 pts (25.4%), and grade 4 in one
patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity., ENETS Center of Excellence
e, Ospedale Sant'Andrea, Via
F. Panzuto).
r B.V. All rights reserved.
M. Rinzivillo et al. / Pancreatology 18 (2018) 198e203 199Conclusions: The present real-world experience shows that sunitinib is a safe and effective treatment for
panNETs, even in the clinical setting of heavily pre-treated, progressive diseases.
© 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.Table 1
Patients' general features.
Feature N %
Male gender 45 56.2
Non-functioning tumors 70 87.5
ECOG performance status
0 58 72.5
1 19 23.8
2 3 3.7
WHO 2017a [3]
NET G1 20 26.3
NET G2 54 71.1
NET G3 2 2.6
ENETS staging
Stage II 1 1.3
Stage III 7 8.7
Stage IV 72 90
ENETS: European Neuroendocrine Tumor Society.
a Data available in 76 patients.Introduction
Pancreatic Neuroendocrine Neoplasms (panNENs), although
considered rare diseases, have been increasing in incidence and
prevalence over the last few decades in both US and European
countries [1,2]. According to the updated World Health Organiza-
tion (WHO) classification [3], they are classified into four different
categories (well differentiated pancreatic neuroendocrine tumors
(panNETs) G1, G2, G3, and poorly differentiated pancreatic neuro-
endocrine carcinoma NEC G3), based on the proliferative index
Ki67 and tumor morphology which, together with tumor burden,
are considered the strongest prognostic factors affecting patients'
clinical outcome [4e7].
The therapeutic scenario of panNETs has dramatically changed
during the last few years, after the introduction of targeted agents
everolimus and sunitinib which are effective in patients with
advanced, well-differentiated progressive tumors [8,9].
Sunitinib is a multi-target agent which effectively inhibits
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a, PDGFR-b, and KIT. Its ac-
tivity in panNETs was initially observed in a Phase 2 trial which
reported an objective response rate of 16.7% [10]. Sunitinib activity
in panNETs has been definitively confirmed in a multicenter Phase
III trial in 2011 [9] which showed, without significantly affecting
patients' quality of life [11], a doubling in median progression-free
survival (PFS) of 11.4 months in patients receiving sunitinib
compared to those treated with placebo, a figure that has recently
been confirmed by the updated data analysis [12].
However, beyond the above-mentioned studies, very scarce data
on panNET patients treated with sunitinib outside the regulatory
trial setting have been published so far.
Thus, this study aimed at analyzing the efficacy and tolerability
of sunitinib in patients with panNETs in a real-world clinical
setting.
Patients and methods
This is an Italian nationwide retrospective analysis of patients
with sporadic panNETs who received sunitinib based on compas-
sionate use or local regulatory authority approval, with the
following inclusion criteria: age >18 years, histologically proven
diagnosis of panNET with well-differentiated morphology, locally
advanced unresectable or metastatic disease, progressive disease
(PD) documented by radiological examinations, ECOG performance
status 2, availability of follow-up data collected according to the
European Neuroendocrine Tumors Society (ENETS) guidelines [13].
Patients with familiar syndromes (i.e. Multiple Endocrine Neoplasia
syndromes, Von Hippen Lindau syndrome) and patients with tu-
mors with poorly differentiated morphology (panNECs) were
excluded from this study.
All patients provided full informed consent before starting
sunitinib treatment. This study was approved by the local ethics
committee of the Rome ENETS Center of Excellence e Sant’Andrea
Hospital.
Methods
Based on the drug dosing schedule [14], sunitinib was given atthe standard dose of 37.5mg daily until PD or intolerable toxicity
occurred, or if informed consent was withdrawn by the patient.
Adverse events were graded according to the Common Termi-
nology Criteria for Adverse Events v. 3.0 [15], and were prospec-
tively collected together with demographic, pathological,
radiological and clinical data at each participating center. A unique
computerized datasheet was subsequently created, and data was
analyzed retrospectively.
At the time of data analysis, tumors were retrospectively divided
according to the WHO 2017 classification [3] based on the histo-
logical data obtained from the pathological charts collected at each
participating center, where the initial diagnosis was done. The tu-
mor degree of differentiation was reported in all the pathological
reports.
Sunitinib efficacy was assessed by evaluating PFS, OS, and dis-
ease control (DC) rate, which was estimated by the best overall
response (defined as the best radiological tumor response achieved
during treatment according to RECIST 1.0 criteria [16]). Patients
were considered “responders” when DC (in terms of stable disease
(SD), partial response (PR), or complete response (CR)) was ach-
ieved as best overall response, otherwise they were considered
“non-responders”.
Data is expressed as median and 25the75th interquartile ranges
(IQR). Progression-free survival was defined as the interval be-
tween sunitinib therapy initiation and treatment discontinuation
due to PD or patient death from any cause, whichever occurred first.
Overall survival was defined as the interval between sunitinib
therapy initiation and death from any cause. Both PFS and OS were
assessed using the Kaplan-Meier method, and the results were
compared by log-rank test. Risk factor analysis to identify variables
associated with increased risk of progressionwas performed by Cox
proportional-hazard regression analysis. Statistical analysis was
performed by Medcalc® v.17 software (MedCalc Software (www.
medcalc.org)).
Results
A total of 80 patients, median age 59 years (IQR 28e67), were
included in the present study. Patients' general features are
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(95%), and was assessed in all but one of them by Ki67 immuno-
histochemical analysis (in the remaining patient, grading was
assessed by mitotic count). Overall, median Ki67 was 5% (IQR 3%e
10%), and most patients (71.1%) had NET G2 neoplasm.
A total of 43 patients (53.8%) had undergone surgery before
sunitinib treatment. Although surgery had been considered radical
in 15 of them (18.8%), all underwent disease recurrence during
subsequent follow-up.
All but one patient (98.8%) had received previous medical anti-
tumor treatments before sunitinib initiation. The most frequent
treatments received were somatostatin analogs (76 patients, 95%),
everolimus (64 patients, 80%), systemic chemotherapy (46 patients,
57.5%), and peptide receptor radionuclide therapy (PRRT) (45 pa-
tients, 56.3%). Overall, 53 patients (66.3%) had received three or
more therapeutic regimens before sunitinib initiation, with 24
patients (30%) having been treated with four previous systemic
treatments.
Median interval between initial panNET diagnosis and sunitinib
initiation was 66 months (IQR 39.5e98 months). Median duration
of treatment was 7 months (IQR 5e12 months). Somatostatin an-
alogs therapy was associated with sunitinib in 47 patients (58.7%).Efficacy
Overall, median PFS was 10 months (95% CI 7e12 months)
(Fig. 1). A total of 53 patients (66.2%) experienced PD during suni-
tinib treatment. Similar risk of PD was observed between NET G1
and NET G2 tumors, median PFS being 11 months and 8 months,Fig. 1. Progression-free survival in 80 panNrespectively (p¼ .522). No difference was observed in terms of risk
of PD in patients who had received three or more therapeutic ap-
proaches before sunitinib initiation compared to those who had
received two or less previous systemic treatments, median PFS
being 9 months and 10 months, respectively (p¼ .632). Similar
median PFS was observed in patients who had been pre-treated
with everolimus compared to those who had not received it, me-
dian PFS being 10 months and 7 months, respectively (p¼ .802).
Although not statistically significant, a double median PFS was
observed in patients who received somatostatin analogs in com-
bination with sunitinib compared to patients who were treated
with sunitinib alone (12 months and 6 months, respectively;
p¼ .152).
When risk factor analysis was performed, no variable was
significantly associated with increased risk of progression (Table 2).
Median overall survival from sunitinib initiation was 40 months
(95%CI 21e47 months) (Fig. 2). A total of 28 patients (35%) died
during sunitinib treatment.
Overall, DC rate was 71.3% and SD was the most frequent
observed response, being reported in 43 patients (53.8%). Further-
more,14 responders (17.5%) achieved PR during treatment, whereas
the remaining 23 patients (28.7%) were non-responders to suniti-
nib, since they underwent PD as best overall response.Tolerability
Overall, 59 patients (73.8%) experienced AEs during sunitinib
treatment, which were mild (grade 1e2) in most cases (n¼ 43,
72.9%). Grade 4 toxicity was reported in one single patient (1.7%) asET patients during sunitinib treatment.
Table 2
Predictors for PD during sunitinib treatment.
Univariate analysis
Variable HR 95%CI p
Performance status ECOG 1e2 vs 0 1.64 0.92e2.91 .089
NET G2 vs NET G1a 1.28 0.65e2.52 .459
Ki67b 1.01 0.96e1.07 .461
Concomitant somatostatin analog 0.68 0.38e1.21 .195
3 previous therapeutic lines (vs 2) 1.12 0.60e2.09 .709
Interval between NEN diagnosis and sunitinib beginningc 0.99 0.98e1.00 .292
a According with WHO 2017 classification [3].
b For each increasing Ki67% unit.
c For each increasing month.
Fig. 2. Overall survival in 80 panNET patients during sunitinib treatment.
Table 3
Most frequent adverse events during sunitinib treatment.
Adverse event Overall Grade 1-2 Grade 3-4
Hypertension 18 (22.5%) 15 (18.8%) 3 (3.8%)
Asthenia 18 (22.5%) 12 (15%) 6 (7.5%)
Diarrhea 16 (20%) 16 (20%) e
Neutropenia 15 (18.8%) 8 (10%) 7 (8.8%)
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(25.4%). Most frequent AEs, occurring in >5% of patients, are
detailed in Table 3. Due to toxicity, 32 patients (40%) required
temporary sunitinib discontinuation, whereas a daily dose reduc-
tion was required in 24 patients (30%). A total of 6 patients (7.5%)
definitively stopped treatment due to toxicity.
A similar safety profile was observed irrespective of the kind of
previous treatments. In fact, of patients (n¼ 16) who experienced
grade 3e4 AEs, 13 pts (81.2%) had received everolimus, 12 pts (75%)
systemic chemotherapy, whereas 11 pts (68.7%) had been treated
with PRRT.Mucositis 14 (17.5%) 12 (15%) 2 (2.5%)
Palmar-plantar erythrodysesthesia 8 (10%) 7 (8.8%) 1 (1.3%)
Thrombocytopenia 7 (8.8%) 6 (7.5%) 1 (1.3%)
Stomatitis 5 (6.3%) 5 (6.3%) e
Fever 5 (6.3%) 4 (5%) 1 (1.3%)Discussion
This study confirms activity and tolerability of sunitinib inpatients with advanced, progressive panNETs even when heavily
pre-treated.
Table 4
Sunitinib in pancreatic neuroendocrine neoplasms.
Median PFS Median OS DC rate
Phase III trial [9] 11.4 months 38.6 months 72%
Phase IV study, preliminary data [21] 11.1 months 37.8 months NAb
Other studies (9a, 20, 21, 22a) 7.7e15.3 months 22.5 months e not reached 75%e86.7%
Present study 10 months 40 months 71.3%
DC ¼ disease control (stable disease þ partial response þ complete response).
a This study reported 24.5% objective response rate (CR þ PR).
b Main endpoint was time to progression.
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available on sunitinib in panNETs outside the multicenter Phase III
trial [9] is scarce. Indeed, data from real-world studies may help
physicians to fill the gap between the rigorous experimental design
of regulatory trials and real clinical practice.
The study by Ito et al. [20] included only twelve patients with
panNETs, confirming overall the major findings previously reported
in the Phase III trial. A mixed population including 44 patients with
pancreatic and gastrointestinal NETs was included in the paper by
Yoo et al. [21], who observed a lower sunitinib activity in NETs other
than pancreatic, as previously reported [10]. An additional retro-
spective analysis was published by Wang et al. [22] on 60 panNETs,
mostly without previous systemic medical treatment (n¼ 53,
88.3%), again confirming sunitinib overall efficacy and safety.
Furthermore, preliminary data from a completed Phase IV study
has recently reported the treatment activity and safety also in naïve
patients who received sunitinib as first-line therapy [23].
The present study reports the clinical experience on a relatively
large set of heavily pre-treated panNET patients who received
sunitinib in a real-world setting, with efficacy and tolerability data
similar to that observed in the Phase III trial [9]. However, several
differences in terms of patients' features and study design (pro-
spective vs retrospective) need to be taken into account when
comparing the present study with that trial. In fact, this study in-
cludes a significantly higher proportion of non-functioning tumor
(87.5% vs 49%), with higher Ki67 (49.3% of patients with Ki67> 5%
vs 36%), longer interval between initial panNET diagnosis and
sunitinib initiation (5.5 yr vs 2.4 yr), and a lower proportion of
patients who had received surgery before sunitinib initiation
(53.8% vs 88%). Although the number of previous therapeutic reg-
imens was not specified in the Phase III trial, it is reasonable that
the population evaluated in the present study includes more
heavily pre-treated patients. In fact, almost all patients had
received somatostatin analogs (95% vs 35% in the Phase 3 trial), and
a significant proportion had also been pre-treated with everolimus
or PRRT (80% and 56.3%, respectively, vs none in the Phase III trial).
Conversely, a similar proportion of patients had been pre-treated
with systemic chemotherapy (67.5% vs 66% in the Phase III trial).
Based on these considerations, we can assume that a different
population with more aggressive, heavily pre-treated patients and
longer disease clinical history was included in the present study.
This figure might be related to different reasons, including the late
reimbursement approval for sunitinib in panNETs which, in Italy,
occurred in 2015.
Nevertheless, the treatment efficacy was consistent with data
reported by other studies performed in different clinical settings, in
terms of median PFS, median OS, and DC rate (Table 4).
As far as the concomitant use of somatostatin analogs is con-
cerned, a relatively high proportion of patients received the com-
bined therapy (somatostatin analogs plus sunitinib) in the present
study (58.7%), although most patients (87.5%) had non-functioning
tumors. Although partly unexpected, this figure confirms the
common clinical practice of maintaining somatostatin analogswhen beginning targeted therapies irrespective of the tumor
functional status, as reported by other studies [24e26]. The longer
median PFS observed in patients who received the combined
therapy in comparison with those who were treated with sunitinib
alone might suggest a possible synergic activity between somato-
statin analogs and targeted therapies. However, due to the rela-
tively low number of patients and the retrospective study design,
this hypothesis cannot be confirmed by significant solid data. Un-
derstanding the real impact of the association of somatostatin an-
alogs to targeted agents on treatment efficacy still remains a
challenge, given the conflicting results that have been reported on
this topic so far [25,27e29].
Neither the comparison between NET G2 tumors vs NET G1
tumors nor the number of previous antitumor therapeutic lines
were predictors for different response to sunitinib in terms of
increased risk of PD (Table 2) (a comparison with NET G3 was not
feasible due to the low number of patients included in this sub-
group, n¼ 2). This figure seems to disagree with data from the
Phase III trial (which reported a lower capability of sunitinib to
reduce the risk of PD in patients with tumor with Ki67> 5%, and
with 2 previous therapeutic lines [9]), a difference which may be
again related to the different patients' features. Interestingly,
sunitinib efficacy was maintained in the subgroup of patients who
had been pre-treated with everolimus.
As far as tolerability is concerned, neutropeniawas confirmed as
the most frequent grade 3e4 AE, with a proportion of study pa-
tients similar to that of the Phase III trial [9] (8.8% vs 12%, respec-
tively). Conversely, several AEs (i.e. diarrhea, nausea, vomiting,
fatigue, hair-color changes) were more rarely observed in this
study, although their frequencies were similar to those reported by
other studies investigating sunitinib in panNETs [21,22]. As previ-
ously reported [24], these differences may be due to the higher
awareness of physicians who participated in the Phase III trial
compared to the real-world clinical setting and, again, to the
retrospective design of this study.
Conclusions
Despite inherent limitations mainly due to the retrospective
study design, which is a common feature of the studies investi-
gating NENs due to their rarity, the present real-world experience
shows that sunitinib is a safe and effective treatment for panNETs,
even in the clinical setting of heavily pre-treated, progressive
diseases.
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